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ABSTRACT 
Aaron A. Cook: Calcium-induced structural rearrangements release  
autoinhibition in the Rap-GEF, CalDAG-GEFI 
(Under the direction of Wolfgang Bergmeier and John Sondek) 
 
When blood vessels are injured, extracellular matrix is exposed leading to the recruitment 
and activation of platelets where they aggregate to staunch bleeding. To aggregate, platelets 
require the release of intracellular calcium linked to the activation of Rap1B. Rap1B is a small 
GTPase that is activated by guanine nucleotide exchange factors (GEFs) related to Cdc25. 
CalDAG-GEFI is a Cdc25-related GEF likely to coordinate increased calcium levels with Rap1B 
activation in platelets. However, the molecular details for how CalDAG-GEFI activates Rap1B 
are unknown. Here we show that calcium directly regulates CalDAG-GEFI to activate Rap1B. In 
particular, purified CalDAG-GEFI robustly activated Rap1B using a fluorescence-based 
nucleotide exchange assay and exchange was lost when CalDAG-GEFI was treated to chelate 
calcium. Conversely, exchange was fully restored by reintroduction of calcium. Furthermore, 
substitution within the calcium binding loop of either EF hand crippled the exchange capacity of 
CalDAG-GEFI. Indeed, substitution in both EF hands abrogated calcium-dependent nucleotide 
exchange on Rap1B. Many EF hands undergo calcium-dependent conformational 
rearrangements. To better understand potential conformational rearrangements that regulate 
CalDAG-GEFI, the differential uptake in deuterium between active CalDAG-GEFI and the form 
with both EF hands disabled was measured. These studies highlighted calcium-induced 
conformational rearrangements in two regions: i) both EF hands, and ii) the linker connecting the 
 iv 
EF hands and Cdc25 domain. Previous work on CalDAG-GEFII showed that the equivalent 
linker lies across the surface of the Cdc25 domain needed to engage Ras GTPases and proposed 
that the linker is displaced from this surface by calcium-dependent rearrangements in the EF 
hands. To test a similar model for CalDAG-GEFI, the linker was mutated and shown to be 
required for autoinhibition. In particular, substitution of valine 406 in the linker fully restored 
exchange capacity of CalDAG-GEFI with both EF hands disabled. Overall, the data support a 
model whereby the EF hands work in concert, undergoing conformational rearrangements that 
control the placement of the linker to finely tune the activation of CalDAG-GEFI in platelets. In 
platelets, CalDAG-GEFI engages Rap1B at the inner leaflet of the plasma membrane. Future 
studies will define the role of membranes on the calcium-dependent regulation of CalDAG-
GEFI.  
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CHAPTER 1: INTRODUCTION 
Blood is comprised of three main types of cells: i) red blood cells that carry oxygen to 
tissue, ii) white blood cells that fight off infection, and iii) platelets that prevent blood loss at 
sites of vascular injury. The data gathered from my studies and described in this dissertation 
pertain only to platelet function and principally address the mechanisms for how calcium 
regulates the activity of calcium and diacylglycerol-regulated guanine nucleotide exchange factor 
(CalDAG-GEFI), and the small GTPase Ras-associated protein (Rap) 1B in platelets. These two 
proteins mediate essential platelet functions necessary for proper hemostatic plug formation at 
the site of vascular injury (1, 2). 
When the endothelial lining of blood vessels is injured, the extracellular matrix (ECM), 
becomes exposed, which serves as a substrate activating platelets as they flow out of the 
compromised blood vessel (3). One way platelet activation can be quantified is by measuring 
their change in morphology, from a discoid shape to a star-like shape with numerous filopodia, 
and by measuring the amount of activated adhesion receptors, integrin aIIbb3 on their plasma 
membrane, activated platelets adhere tightly to each other albeit, indirectly. Fibrinogen, a protein 
secreted in the plasma in blood binds to the activated integrins on adjacent platelets to form 
platelet aggregates that continue to accumulate, eventually recruiting enough platelets to form a 
stable hemostatic plug that prevents further bleeding (4). 
Hemostatic plugs do not form unless there is integrin aIIbb3 in the active state on platelet 
membranes. These integrin’s become activated by an integrin activation complex (IAC), formed 
by proteins that are recruited to the integrins cytoplasmic tail, primarily Kindlin3, vinculin, talin, 
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and Rap isozymes in response to an increase in calcium concentration in the cytosol (5). 
Subsequently, the IAC binds to the cytoplasmic tail of the integrins causing them to undergo 
conformational rearrangements that are transmitted back through the membrane necessary for 
integrin activation. Increases in the intracellular calcium concentration coincide with high levels 
of activated integrin on the platelet surface. Improper regulation of calcium cripples the platelets’ 
ability to function normally because they cannot activate aIIbb3 on their surface (6, 7). For 
example, integrin activation is dramatically reduced in platelets that have defective calcium 
channels (8, 9). These platelets are dysfunctional because calcium cannot be released from the 
dense tubular system (DTS). Clearly, calcium is important for platelet function, but the 
mechanism linking calcium to integrin aIIbb3 activation is unknown (10). 
The IAC is critical for inside-out activation of integrins. Rap1B is a molecular switch, 
cycling between active and inactive state. Rap1B is 'on' or active when bound to GTP and 'off' 
when bound to GDP. Platelets express all Rap isozymes. However, Rap1B is the most abundant 
isozyme, and comprises nearly 0.1% of total platelet proteins (11). The abundance of Rap1B 
emphasizes its importance in platelet function. Platelets from genetically modified mice lacking 
Rap1B, have many defects including a marked reduction in integrin activation in response to 
agonist stimulation. These findings are important because they provide a link between integrin 
activation and Rap1B and delayed aggregation (12). 
Enzymes that activate small GTPases are guanine nucleotide exchange factors or GEFs. 
They do so by increasing the rate of nucleotide exchange and are divided into different GEF 
families that have unique regulatory mechanisms and target different GTPases. One such family 
of GEFs has specific activity towards the Ras-superfamily of small GTPases. These GEFs are 
unique because they contain a catalytic, cell-division-cycle (Cdc) 25 domain which is the binding 
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surface that interacts specifically with Ras-family proteins (13-16). Interestingly, the most 
abundant GEF in platelets is a Rap-specific GEF, CalDAG-GEFI (17, 18). Platelets from mice 
lacking CalDAG-GEFI have normal calcium regulation but showed a dramatic reduction in Rap 
signaling and integrin activation. These findings suggest a link between CalDAG-GEFI, Rap1B, 
and integrin aIIbb3 signaling pathways. However, to determine the molecular mechanisms 
regulating CalDAG-GEFI, my work focused to determining how CalDAG-GEFI is regulated and 
define whether calcium is directly activating CalDAG-GEFI, required for proper platelet 
function. 
Platelets lacking CalDAG-GEFI have normal calcium mobilization but a marked delay in 
Rap1B activation and aIIbB3 integrin activation. However, these platelets eventually do form a 
hemostatic plug. These data suggest two facts about Rap1B activation: 1) There is more than one 
phase of Rap1B activation, and 2) the early phase of Rap1B activation requires CalDAG-GEFI 
activity. Because there are multiple phases to Rap1B activation, we set out to determine the 
biochemical function of calcium in the first phase of Rap1B activity whether calcium interacts 
directly with CalDAG-GEFI (2). To answer this question, we developed a functional assay to 
measure nucleotide exchange on Rap1B; we use purified CalDAG-GEFI and Rap1B to 
determine whether calcium directly regulates CalDAG-GEFI activity. Thus, my thesis work 
addressed the following aims: 
1) Determine whether CalDAG-GEFI activity is calcium-dependent. 
2) Determine the conformational rearrangements in CalDAG-GEFI caused by calcium 
binding. 
3) Define regulatory domains that control CalDAG-GEFI activity. 
 4 
The following chapters describe key concepts of platelet biology pertinent to my studies: 
an extensive summary of platelet-receptor activation, calcium mobilization, the biochemical and 
functional role of calcium-binding EF hand domains, the regulation of Rap isozymes, and how 
the family of Cdc25 domain GEFs are regulated. These chapters will provide the context 
necessary to understand the importance of my findings, as discussed in my published work and 
work that is under review, describing how CalDAG-GEFI is regulated by: a) negative-feedback 
loops sustained through extracellular-signal-regulated kinase (ERK) 1/2 signaling pathways and 
b) Calcium-induced structural rearrangements release autoinhibition in the Rap-GEF, CalDAG-
GEFI. 
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CHAPTER 2: PLATELET-RECEPTOR SIGNALING, CALCIUM 
REGULATION, AND EF HAND BIOLOGY 
Platelets are shed into the vascular system from megakaryocytes that reside in bone 
marrow, spleen and lungs after they mature and undergo apoptosis, releasing platelets. Each 
megakaryocyte is capable of producing 2000-5000 platelets that are vital for the development 
and maintenance of our vasculature (19). In the developing fetus, platelets are required for the 
proper segregation of the lymphatic and blood vascular systems, while in adults, the major 
functions of platelets are to prevent blood loss and promote wound healing. 
Platelets in circulation have a discoid shape and are the smallest cells circulating in the 
blood stream. Platelets detect an injured vessel when the ECM, lining the outside of the vessel, 
becomes exposed (20). The exposed ECM then serves as substrates for receptors on the platelet 
surface (21). When these receptors are activated they transmit signals across the membrane, 
initiating a cascade of signaling events that result in dramatic changes in platelet morphology and 
their adhesive properties (22, 23). In this section, I will discuss platelets in the context of three 
phases of hemostatic plug formation: i) platelet activation and firm adhesion to the ECM, ii) 
platelet-platelet cohesion, and iii) clot retraction.  
Platelet receptors signaling  
To begin hemostatic plug formation at a site of vascular injury, platelets first become 
tethered to the exposed ECM by von Willebrand factor (vWF), a multimeric plasma protein that 
binds to collagen, a major component of the ECM (23, 24). Platelets can bind collagen through 
vWF with constitutively active glycoprotein (GP) Ib/IX/V receptors on their surface. The fast 
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on/off rate of GPIb/V/IX binding to vWF allows platelets to be tethered and detached over a 
lawn of vWF, required to recruit platelets to sites of injury where the shear forces inhibit the 
interaction of other platelet receptors that engage the ECM but have slower binding rates. For 
example, platelets have receptors that directly bind collagen however, without tethering to 
collagen through vWF, platelets would have a lower incidence of binding to the ECM directly 
because of the shear forces (20). As a result, platelets would accumulate more slowly at the site 
of injury, hindering hemostatic plug formation. However, once GP Ib/V/IX engages vWF, 
signals are transmitted across the membrane to activate proteins at the inner leaflet to produce 
new signals being transmitted back across the membrane, activating two platelet receptors that 
directly bind collagen (25). 
GP VI and a2b1 integrins are receptors on the plasma membrane, bind collagen and 
enhance the calcium signals propagated by GP Ib/IX/V necessary for firm platelet adhesion (26). 
GPVI is an immunoreceptor tyrosine-based activation motif (ITAM) receptor activated when its 
cytoplasmic tail is phosphorylated by Fyn/Lyn kinases (27). These kinases are recruited to the Fc 
gamma chain (ITAM)-containing intracellular tail of GPVI. The interaction, between the 
cytoplasmic tails, enhances Fyn/Lyn kinase activity and enhances clustering of GPVI within the 
membrane. Collagen binding also leads to GPVI clustering, and transmits a signal back across 
the membrane, amplifying the intracellular Fyn/Lyn kinase activity (27). These inside-out signals 
propagated by GVI clustering, activates another collagen receptor on the surface of platelets, 
a2b1 integrin. 
The  a2b1 integrin is a cell surface receptor, formed by an alpha-two and beta- three 
heterodimer that spans the plasma membrane. The inside-out activation of a2b1 is propagated by 
phosphorylation of its cytoplasmic tail, at the inner leaflet of the plasma membrane, and the 
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formation of the integrin activation complex (IAC) (5, 28-30). The IAC includes proteins such as 
talin, kindlin3 and the small GTPase, Ras-associated protein (Rap) 1. Assembly of the IAC at the 
cytoplasmic tail of the b subunit leads to a conformational change in a2b1, shifting it from a low 
affinity state to a high affinity state. Clustering of a2b1 receptors enhances the avidity for 
collagen (4, 31, 32). Platelets tethered and adhered to collagen form a ring that encircles the 
injury site and recruit additional platelets (24). These newly recruited platelets adhere to the 
platelets in the ring, and to one another, forming a monolayer, adhering in concentric circles, 
eventually closing the wound. An important intracellular event downstream of activated 
receptors and platelet adhesion is the release of stored calcium into the cytosol (7, 33). Previous 
work demonstrated a close correlation between calcium mobilization and integrin activation on 
the platelet surface. Importantly, the kinetics of the activation of Rap1, a crucial member of the 
IAC, correlates with calcium mobilization and integrin activation; both calcium and Rap1 are the 
major focus of my studies and in chapter 5, I will discuss the precise mechanism for how Rap 
isozymes become activated downstream of calcium release. 
Protease activated receptor (PAR) isozymes 1 and 4 are two G-protein coupled receptors 
(GPCR) on the surface of platelets that transmit signals across the membrane to sustain robust 
calcium signals that began when platelets tethered to collagen (34). PAR receptors are the 
conduit for transmitting signals from ligands produced by the coagulation pathways. The 
coagulation pathways activate proteins in the blood plasma at sites of vascular injury and are 
important throughout the process of hemostatic plug formation. Despite the importance of these 
pathways, the mechanistic details of how all of the proteins activated by these pathways, will not 
be discussed. However, thrombin is a protease activated by the coagulation pathway, and is 
mentioned here, because it activates PAR receptors (35). Thrombin cleaves a portion of the N-
 8 
terminus of the PAR receptor, between arginine 41 and serine 42, revealing a new N-terminus 
that becomes the activating ligand for the receptor itself. All PAR receptors are activated by 
thrombin that is sustained by high concentrations of intracellular calcium.  
Sustained signals through PARs cause platelets to secrete the contents of their granules 
into the extracellular space. Adenosine diphosphate (ADP), is one of the molecules released from 
granules and is an important substrate for autocrine and paracrine signaling.  
Autocrine and paracrine signals positively regulate platelet activation insuring that 
platelet signaling, in and around the hemostatic plug, is robust and sustained. (2, 21). Cohesion 
between platelets, when platelets adhere to one another, builds layers of platelets, stabilizing 
hemostatic plugs over holes in vessels. Platelet cohesion provides a means for relaying both, 
outside-in and inside-out signals from surface receptors, unifying the activation state of all the 
platelets in these layers by promoting granule secretion (22). Interestingly, platelets within the 
hemostatic plug secrete two types of granules; dense granules, containing ligands such small 
molecules, and alpha granules containing peptides and proteins (36, 37). The granule releasates 
activate receptors both on platelets from which they are released and receptors on platelets in 
close proximity, mechanisms known as autocrine or paracrine signaling, respectively. Although, 
many receptors are important for autocrine and paracrine signaling, I will only discuss two 
important receptors on the platelet surface: the P2Y receptors for Adenosine diphosphate (ADP), 
and aIIbb3 integrin receptors for fibrinogen and fibrin. 
P2Y1 and P2Y12 receptors on platelets surface is activated by ADP. P2Y1 receptors 
transmit a weak signal in response to ADP, producing a small burst of calcium in cytosol with no 
significant impact on the formation of a hemostatic plug (38). In contrast, P2Y12 signals do not 
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signal through calcium, but provide robust signals through Phosphatidylinositol-3-kinase (PI3K) 
which sustains the activity of Rap1 isozymes and subsequently, aIIbb3 integrin (22, 39, 40). 
aIIbb3 integrins are platelet-specific adhesion receptors and are the most abundant 
receptors on their surface (11). These integrins are activated through inside-out signaling 
pathways and form a high-affinity conformation, by the identical mechanism as a2b1 integrins, 
as previously discussed. Activated aIIbb3 in-turn, transmits signals back across the membrane, 
providing outside-in signals. The aIIbb3 integrins are important for all phases of platelet 
adhesion and are thus crucial for hemostatic plug formation. 
Fibrinogen, a protein produced in the liver, circulates within the bloodstream. Within the 
hemostatic plug, fibrinogen is the ‘glue’ that holds platelets together. Like vWF, fibrinogen acts 
like a tether between platelets, linking them together through binding to activated aIIbb3 
integrins. 
The final phase of platelet plug formation requires both, the proteolytic cleavage of 
fibrinogen to form fibrin, and the contraction of the actin cytoskeleton within each platelet, 
forming a stable and dense hemostatic plug that can withstand the shear forces exerted by blood 
flow and has the flexibility to withstand contractions and dilations by the blood vessel (41). To 
form a more stable hemostatic plug, fibrinogen is cleaved by thrombin to form fibrin. Fibrin self 
assembles into longer fibrin strands and the platelet- fibrin interaction provides the strength and 
resilience to the hemostatic plug to withstand the contraction of platelets as part of the final 
phase of plug formation, clot retraction (37). 
Platelet retraction results from rearrangements of their actin cytoskeleton. This in turn, 
retracts the entire plug, but maintains the platelet-fibrin bridges while trapping immune cells. 
Platelets adhere tightly to one another and to the ECM and ultimately retract as a unit straining 
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their adhesions to collagen, and the cohesion between one another. Platelet retraction stabilizes 
the hemostatic plug, promotes the recruitment of more immune cells, and seals off the wound to 
prevent further blood loss. Once the platelets are in their final contracted state, they will 
eventually become necrotic, but will remain in the hemostatic plug throughout the healing 
process; bound to collagen in the ECM and linked together by fibrin. In the end, the hemostatic 
plug is broken down by proteases and removed by phagocytic immune cells (22). 
As outlined above, a critical event during platelet activation is the release of calcium 
from the intracellular stores of platelets and the influx of calcium through ion channels in 
membranes. The concentration of calcium in platelets fluctuates throughout their lifetime in 
circulation. The release of stored calcium induced by cellular activation, dramatically increases 
its concentration in the cytoplasm of. High calcium concentrations are sustained throughout all 
phases of hemostatic plug formation because of autocrine and paracrine signals required for 
aIIb3 integrins in platelets. Molecular mechanisms of calcium release and calcium regulation 
downstream of these will be discussed in greater detail in the following section. 
Mechanisms for regulating calcium in platelets 
In this section I will discuss two main aspects of calcium regulation in platelets, calcium 
mobilization from inner stores, and calcium transport from the extracellular space into the 
cytosol. Critical for the generation of the calcium signal is the activation of phospholipase (PLC) 
isozymes, which are located at the inner leaflet of the plasma membrane (42). Once activated 
downstream of GPCR or ITAM receptors, PLC beta (b) and gamma (g) isozymes hydrolyze 
phosphatidylinositol (4,5) phosphate (PIP2), on the glycerol side of the phosphodiester bond. 
PIP2 hydrolysis produces two important second messengers, diacylglycerol, (DAG), a lipophilic 
fatty acid chain which remains in the membrane, and inositol triphosphate, (IP3) a soluble 
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compound, that diffuses throughout the cytosol (38). DAG is an important substrate for 
activating many downstream signaling networks, most notably, protein kinase signaling. DAG 
also activates some CalDAG-GEF isozymes, but not CalDAG-GEFI. CalDAG-GEFI is the focus 
of my work thus, activation of other CalDAG-GEF isozymes by DAG is only pertinent because 
it contrasts the activation mechanism of CalDAG-GEFI. Instead, I will focus on the more 
pertinent second messenger IP3, because it binds to inositol triphosphate receptors (IP3R) in the 
dense tubule system (DTS), causing a dramatic increase in cytosolic calcium concentrations 
required for CalDAG-GEFI activation (43). 
The DTS is an organelle similar to the endoplasmic reticulum of other cell types. It is 
unique to platelets and is their main storage compartment for calcium. The IP3R is the main 
calcium channel in the DTS, which remains closed in the absence of receptor signaling, keeping 
calcium sequestered from the cytosol. Once receptors become activated, the activity of PLC 
increases producing a bolus of IP3 that binds to and opens IP3R channels in the DTS, allowing 
calcium to flow into the cytoplasmic space. The result of this is a significant increase in the 
levels of calcium in the cytoplasm, from ~60 nM to nearly 1 µM (7). This dramatic increase in 
calcium concentration triggers further downstream signals, including the activation of CalDAG-
GEFI. Although, calcium released from the DTS produces a rapid increase in calcium 
concentration in the cytosol, the DTS is only a finite source of free calcium. As previously 
discussed, there are high concentrations of calcium sustained throughout hemostatic plug 
formation. Thus, platelets depend on additional proteins that can form calcium channels localized 
in the plasma membrane (44-47). When calcium stores are depleted from the DTS, calcium 
sensing proteins in the DTS membrane, the Stromal Interaction Molecules (STIMs), are 
activated. Activated STIM binds the calcium release-activated calcium channel protein, Orai1, 
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and clusters it in the plasma membrane forming a channel. Calcium is actively transported back 
into the cytoplasm through the Orai1 channel; a mechanism called store-operated calcium entry 
(SOCE) (48). 
STIM isozymes (1 and 2) are multi-domain, transmembrane proteins, which form dimers 
in the DTS membrane. STIM proteins sense calcium in the DTS with their N-terminal EF hand 
domain, which is localized to the inner leaflet of the DTS membrane. In the absence of agonist 
stimulation, the concentration of calcium in the DTS remains high. Therefore, the EF hand in 
STIM isozymes are bound to calcium However, the EF hand has a low affinity for calcium so, 
once calcium is mobilized from the DTS, it is displaced from the EF hand causing STIM 
isozymes to cluster (43). Orai isozymes are transmembrane proteins that form dimers when they 
are in the inactive state and bind to calcium channels in the plasma membrane to prevent calcium 
transport from the extracellular space into the platelet cytosol. Once STIM isozymes are 
clustered they recruit Orai dimers away from the calcium channels, allowing them to form 
tetramers in the plasma membrane which allows for SOCE. SOCE serves two roles: maintain 
high calcium concentrations in the cytosol and restore calcium to the DTS (46). Once the 
calcium concentration in the DTS is sufficiently high, calcium binding to the EF hands is 
restored, the STIM-Orai complex is dissolved.  
Platelets use additional ion channels in their plasma membrane to transport calcium into 
their intracellular space (46). Once released into the cytosol, calcium binds and activates various 
signaling proteins. Many of these proteins rely on different calcium binding domains, including 
the well-known EF hand domain. Before moving on to the next chapter, I will briefly discuss the 
biology of EF hands, namely, how EF hands coordinate calcium binding, and the conformational 
rearrangements in EF hand proteins induced by calcium. 
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The function and calcium-binding properties of EF hand domains 
Calcium ions serve diverse functions in proteins and bind these proteins to either, 
enhance protein stability, or regulate enzyme catalysis (49). Proteins that bind calcium ions to 
enhance their stability, typically, have calcium binding pockets formed by multiple domains 
within close proximity to each other, and calcium binding is necessary to maintain their 
secondary structure (50, 51). In contrast, proteins that bind calcium ions to regulate their 
catalytic activity, have unique calcium binding sites, made up of a single domain, the EF hand. 
The EF hand nomenclature comes from the relationship between their two helices 
connected by a loop, (helix-loop-helix, HLH). Classically, the N- and C-terminal helices are 
designated by ‘E’ and ‘F’ helix, respectively (52). The tertiary structure of the HLH when 
superimposed on the forefinger and thumb of a person's right hand, is modeled with the linker 
region represented by the curvature of skin, between the thumb (F helix) and forefinger (E helix) 
(53). While not a rule, EF hands typically come in pairs but, both EF hands within the pair do not 
always bind calcium; an example of this is CalDAG-GEFII protein. Using isothermal titration 
calorimetry, (ITC), Iwig et al., showed that in the isolated pair of EF hands, calcium only bound 
to the N-terminal EF hand (54). 
Calcium ions bind within the loop region in EF hands, with variable affinities. Loop 
regions, typically have 12 residues, however the number and type of residues in the loop do not 
predict the calcium binding affinity. Interestingly, the residues conserved in the loop of calcium-
binding EF hands are well conserved. In particular, positions 1, 3, 5, 7, and 12 which form ionic 
bonds with the calcium ion, providing electrostatic interactions. These interactions help stabilize 
the secondary structure of the HLH. In particular, the glutamate at position 12, provides a 
bidentate, ionic bond with calcium, which is required for calcium binding (55). In addition, 
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calcium binding within the loop region induces conformational rearrangements between the E 
and F helices that are transmitted throughout the protein, often regulating enzymatic function 
allosterically (56).  
When calcium binds to the loop region of an EF hand, the E helix undergoes 
conformational rearrangements relative to the F helix. Figure 1, illustrates the arrangement of a 
calcium-free HLH, overlaid with the arrangement of an HLH bound to a calcium ion. Calcium 
binding to EF hands imposes a pentagonal- bi-pyramidal geometric arrangement within the loop 
that is important for providing the thermodynamic energy required to rearrange the E and F 
helices, making it possible to unpack previously solvent inaccessible, hydrophobic regions.  
EF hands typically pack tightly to the core of the protein through hydrophobic 
interactions between the EF hands and the protein core. Thus, conformational changes induced 
by calcium exposes hydrophobic regions in EF hand proteins that are otherwise solvent 
inaccessible. Exposing these hydrophobic regions promotes protein-protein interactions (57). 
However, substrate binding is not limited to only the proximity of the hydrophobic regions 
exposed by the EF hand movement. Often, the movement of EF hands are translated throughout 
the protein and thus, calcium binding can modulate the tertiary structure of proteins, promoting 
allosteric binding of substrates or its translocation to the hydrophobic membrane. In addition, the 
movement of the helices can also displace regions of a protein that are upstream of the E helix or 
downstream of the F helix. Such is the case for CalDAG-GEFI as proposed by the data presented 
in chapter 5. 
CalDAG-GEFI contains a pair of EF hands, and previous work has shown that in 
isolation, each EF hand binds one calcium ion. However, the consequences of calcium binding 
were not described (PDB: 2MA2) (54). As I mentioned, my studies determined that calcium 
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directly activates CalDAG-GEFI, but the question remained, what was calcium doing to 
CalDAG-GEFI to enhance its catalytic activity? However, to design experiments to answer this 
question, it is important to first understand how guanine nucleotide exchange proteins like 
CalDAG-GEFI, regulate their nucleotide exchange activity. The catalytic domain in CalDAG-
GEFI is a cell-cycle-dependent (Cdc) 25 domain. The biochemical and biophysical mechanisms 
for the regulation of some Cdc25 domain family members have been determined. In the next 
chapter I will discuss some of the mechanisms regulating other Cdc25 domain proteins, which 
helped us to design experiments for studies that determine additional ways that CalDAG-GEFI 
activity may be regulated. 
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Figure 1. The pentagonal bipyramidal geometry of calcium coordination of the EF hand 
domains  
A calcium ion is coordinated by residues 1, 3, 5, 7, 9, 12, and a water molecule. loop 
region. Once calcium is bound within the loop, the adjoining helices are perpendicular to one 
another as in the shape of the forefinger and thumb of the right hand.
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CHAPTER 3: MECHANISMS FOR REGULATING SMALL GTPASES BY 
CDC25 DOMAIN NUCLEOTIDE EXCHANGE FACTORS  
There are approximately 150 small GTPases in eukaryotes. The major isozymes 
discussed here is Ras associated protein (Rap). Rap is a member of the Rat Sarcoma (Ras) 
family. However, the most abundant GTPase expressed in platelets are the five Rap isozymes, 
Rap1A, Rap1B, and Rap2A-C. In particular, Rap1B is expressed 10-fold higher than the other 
Rap isozymes, accounting for 0.1% of total platelet proteins (58). GTPases function like 
molecular switches that are switched off when they are bound by guanosine diphosphate (GDP) 
and switched on when GDP is exchanged for guanosine triphosphate (GTP), a reaction catalyzed 
by a guanine nucleotide exchange factor (GEF) (59). The rate of nucleotide exchange in small 
GTPases is intrinsically slow due to the structural flexibility within SWI and SWII, which 
intermittently displaces the magnesium ion, allowing GTP loading. The concentration of GTP in 
a cell is nearly 10 times that of GDP thus once GDP is released GTP preferentially binds (60).  
Inactive GTPases have a GDP molecule in their nucleotide binding pocket that is 
stabilized by three conserved secondary structural elements: a) the phosphate binding (P) loop, b) 
the switch one (SWI) region, and c) the switch two (SWII) region. Furthermore, an obligate 
magnesium ion stabilizes the GDP (13). The P loop, SWI, and magnesium ion form hydrogen 
bond networks that interact directly with GDP. Importantly, SWII stabilizes the magnesium ion 
within those networks. GEF binding releases GDP by inducing conformational changes in the 
GTPase that push SWII toward the P loop, displacing the magnesium ion, while pulling SWI 
away from GDP allowing for its release, known as the "push-pull mechanism" (59). Once GDP 
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is released, GTP is able to bind, switching the GTPase on. Once the GTPase is turned on, the 
GEF dissociates which allows the magnesium ion to re-coordinate within SWII, stabilizing GTP 
within the nucleotide-binding pocket. (PDB: 3X1W, 3X1X). 
Ras-family small GTPases are activated by multiple GEFs. In turn, some of these GEFs 
activate multiple small GTPases while others are specific to a particular Ras-family isozyme. 
The information presented in this chapter provides myriad biochemical and structure/function 
data to describe the complex and unique regulatory mechanisms for a subset of the GEFs that all 
share a cell-cycle-dependent (Cdc)25 catalytic domain and activate Ras-family GTPases (Figure 
2). 
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Figure 2. Cdc25 domain guanine nucleotide exchange factors 
A, Domain architecture which include: Ras exchange motif (REM), cell-division-cycle 25 
(Cdc25) domain, EF hand (EF), C1 domain, Ras-associated (RA) domain, Dbl homology (DH) 
domain, Pleckstrin homology (PH) domain, Rho GEF domain, Dishevelled, Egl-10, and 
Pleckstrin (DEP) domain, cyclic-nucleotide binding (CNB) domain. 
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The chapter will conclude by detailing the mechanism for how these small GTPases are switched 
off. 
 CalDAG-GEF (RasGRP) subfamily 
The calcium and diacylglycerol-regulated guanine nucleotide exchange factor (CalDAG-
GEF) family consists of four members (I-IV), also referred to in the literature as Rat sarcoma 
(Ras) guanyl-nucleotide exchange-releasing protein (RasGRP) (RasGRP1-4). CalDAG-GEF 
isozymes catalyze nucleotide exchange on both Ras and Rap small GTPases and are composed 
of an N-terminal Ras exchange motif (REM) domain, a catalytic Cdc25 domain, two EF hands, 
and a C1 domain.  
The CalDAG-GEFII-IV isozymes are primarily regulated by DAG and activate Ras and 
Rap isozymes. Interestingly, overexpression of these CalDAG-GEF isozymes transforms certain 
cell types from normal cells to a more cancer-like cell; phenotypes that are associated with 
aberrant signaling downstream of Ras and/or Rap proteins (61). Indicative of this transformation 
are changes in cell morphology, an increased rate of cell division, and prolonged cell survival 
(62). However, the exact regulatory mechanisms for each CalDAG-GEF isozyme attributing to 
these pathological cellular transformations are not well understood. In contrast, some of the 
mechanisms regulating each isozyme under physiological conditions are better understood, 
beginning with CalDAG-GEFII. 
The CalDAG-GEFII is a selective nucleotide exchange factor for Ras isozymes, H-, M-, 
R-Ras1 and R-Ras2, which is highly expressed in distinct portions of the brain and a subset of 
immune cells (16). Although the role of CalDAG-GEFII in neurons is unclear, CalDAG-GEFII 
is required for developing and maintaining a healthy immune system, promoting T cell 
maturation, and proper signaling downstream of B- and T-cell receptors (63). 
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Recent work published by Iwig et al. provided structural and functional data on the 
molecular mechanisms underlying CalDAG-GEFII function. Data from a crystal structure of the 
truncated form of CalDAG-GEFII, lacking the C1 domain, suggests that in the absence of 
calcium CalDAG-GEFII is autoinhibited (PDB: 4L9M). Furthermore, it was shown that calcium 
binds to the N-terminal EF hand in CalDAG-GEFII, and that calcium binding leads to 
conformational changes that perturb an autoinhibitory linker region between the Cdc25 domain 
and EF hand 1. 
Data from a second crystal structure of the isolated C1 domain of CalDAG-GEFII 
revealed another mechanism regulating autoinhibition, suggested by two subunits of the C1 
domains that form coiled-coiled homodimers within the unit cell of these crystals. The C1 
domain of CalDAG-GEFII shares significant sequence homology with the C1 domains in protein 
kinase C (PKC) isozymes, for which DAG binding is best understood. The C1 domain of 
CalDAG-GEFII isozymes binds DAG with nanomolar affinity (Kd»1.5 nM) (64). Functional 
studies using full-length CalDAG-GEFII with substitutions in residues that prevent dimer 
formation, revealed an enhanced nucleotide exchange activity, supporting not only homodimer 
formation in the full-length protein, but suggested that the dimers may be disrupted by DAG 
binding. 
CalDAG-GEFIII is a nucleotide exchange factor for the same repertoire of small 
GTPases as CalDAG-GEFII: H-, M-, R-Ras, and TC21 (65, 66). Cells overexpressing CalDAG-
GEFIII show increased activation of Ras as measured by enhanced levels of phosphorylated 
extracellular signal-related kinase 1/2 (ERK1/ERK2). This enhanced Ras activity was induced by 
treating cells with phorbol ester, a DAG mimetic (67). Upon treatment, CalDAG-GEFIII proteins 
relocalize from the cytosol to both, the perinuclear and plasma membranes (83, 88). This in vitro 
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data provides evidence for how the localization of CalDAG-GEFIII is regulated, but also 
suggests that DAG binding may release an autoinhibited state, allowing for its translocation to 
membranes and subsequent activity. 
The CalDAG-GEFIV isozymes is a selective nucleotide exchange factor for H-Ras (16, 
68). CalDAG-GEFIV has high expression in fetal tissues, specifically the lungs, liver, and 
spleen, whereas in adult tissue, it is expressed predominantly in leukocytes. CalDAG-GEFIV is 
the least studied isozyme in the CalDAG-GEF family. However, data has shown that fibroblast-
like cells overexpressing CalDAG-GEFIV and treated with phorbol esters had enhanced 
recruitment of CalDAG-GEFIV to the membrane, had increased activity of H-Ras isozymes, and 
increased levels of phosphorylated ERK1/ERK2. These data were corroborated by studies using 
another cell type overexpressing CalDAG-GEFIV, which were also transformed, by a Ras-
dependent mechanism, suggesting a possible role for CalDAG-GEFIV as an oncogene (62). 
Ral GEF subfamily 
All members of the Ras-like (Ral) GEF family activate both RalA and RalB isozymes of 
Ral GTPases and is comprised of Ral guanine-dissociation stimulator (RalGDS), Ral releasing 
factor (Rlf), and RalGEF-like (RGL) isozymes (69). RalGEF isozymes are implicated as part of 
the signaling cascades required for endocytosis, gene transcription, cell proliferation, cell 
survival, and the production of second messengers. However, it has been difficult to ascertain 
their true function in these processes because of overlap between their activity and the activity of 
other Ras and Rap nucleotide exchange factors that are implicated in these same processes (70). 
The RalGEF isozymes have three functional domains, an N-terminal REM domain, a 
Cdc25 domain, and (Ras-associated) RA domain. The REM domain allosterically regulates the 
activity of RalGEF isozymes, the catalytic Cdc25 domain catalyzes nucleotide exchange on Ral 
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isozymes, and the RA domain is a binding site for activated Ras isozymes. Activated Ras 
isozymes bind to RalGEFs inducing conformational rearrangements that release an autoinhibited 
state necessary for the normal function of Ral isozymes. Not surprising, oncogenic Ras 
dramatically increases the activation of RalGEFs, leading to enhanced expression of transcription 
factors associated with tumorigenesis (71). Given the effect of oncogenic Ras has on the activity 
of Ral isozymes, Ral has become the target of small molecules for cancer therapy (72). 
Unfortunately, little is known about the mechanism for how RalGEFs are regulated by Ras. Data 
from a crystal structure of the isolated RA domain of one RalGEF, Rlf reveals very little 
information about the effect of Ras on the RA domain in the context of the full-length protein 
(PDB:1RLF) (73). 
Data from a crystal structure of truncated Rlf, lacking the RA domain, in complex with 
Ral, revealed that the activation of Rlf was regulated by residues comprised in a helical hairpin 
structure located in the REM domain (PDB:5CM8, 5CM9) (74). This hairpin structure contains 
hydrophobic residues interacting with Ral to stabilize regions in SWI, both enhancing its 
capacity for nucleotide exchange and promoting the release of Rlf from activated Ral proteins. 
After GTP binds Ral, active Ral dissociates from the Cdc25 domain in Rlf when the helical 
hairpin rotates away from the SWI region of Ral. A structural comparison between apo-Rlf 
protein and Rlf protein in complex with Ral, suggests that once Ral-GTP is released from the 
catalytic binding pocket, the helical hairpin structure becomes disordered and is more closely 
associated with the REM domain. Disorder in the helical hairpin in the absence of Ral, suggests 
that conformational rearrangements in Rlf are necessary to stabilize the secondary structure of 
the hairpin, a possible allosteric mechanism for activating Rlf isozymes. 
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Commonly, small GTPases are localized to the membrane and therefore GEFs must be 
recruited to the membrane to activate them. A proline-rich region at the N-terminus of Rlf, 
upstream of the REM domain, is thought to serve as a ‘flagpole’ to recruit Src-homology (SH) 3 
domain proteins (PDB:4JGW) (75). This SH3 binding site of Rlf may be a docking site for 
interactions with a well-known adaptor protein, growth factor receptor-bound protein (Grb) 2, 
shown to regulate other GEFs by recruiting them to the plasma membrane (76). 
Sos subfamily 
The Son of Sevenless (Sos) family of GEFs consists of the Sos1 and Sos2 isozymes 
whose complex regulatory mechanisms are attributed to their elaborate domain architecture. The 
Sos isozymes contain an N-terminal, histone binding domain, a DH/PH domain, PH/REM helical 
linker, REM domain, Cdc25 domain, and C-terminal Grb2/E3b binding domain. A wealth of 
data about the function of some of these regulatory domains has been compiled from 
biochemical and crystallographic studies defining key aspects for how individual domains 
contribute to the activity of Sos isozymes such as their cellular localization, their dual specificity 
for Rho and Ras isozymes, and positive-feedback mechanisms (77). 
Inactive Sos isozymes are primarily localized to the cytosol but are recruited to the inner 
leaflet of the plasma membrane with the help of adaptor proteins that sense changes in the 
composition of phospholipid composition of the membrane- namely an increase in the 
concentration of PIP2. The DH domain of SOS binds PIP2, but sterically occludes by the PH 
domain, preventing the ability of Sos to activate Rac isozymes until it interacts with PIP2. Upon 
the conversion of PIP2 in the membrane the PH domain binds and is displaced and the exchange 
capacity of Sos for Rac isozymes is enhanced, specifically at membranes (78).In addition, the 
conformational rearrangements in the DH/PH domain enhances the ability for Sos isozymes to 
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exchange nucleotide on Ras isozymes, suggesting the specificity of Sos for both Rac and Ras 
isozymes is allosterically regulated. 
Data from a crystal structure of a truncated version of Sos1, containing the DH-PH, 
REM, and Cdc25 domains corroborates the biochemical data for the allosteric regulation of Sos 
isozymes. These data revealed that in the absence of PIP2, the DH-PH domain is in a bent 
conformation creating contacts between the REM and Cdc25 domain (79). This structural 
arrangement of the DH-PH domain is thought to be an autoinhibitory mechanism as determined 
by the reduced capacity for these truncated Sos proteins to exchange nucleotide on Rac and Ras 
isozymes. Concomitantly, biochemical data showed that Sos1, lacking the DH-PH domain has an 
enhanced capacity for nucleotide exchange on Rac (76). In addition, data from another crystal 
structure of Sos1, containing just the REM and Cdc25 in complex with Ras, defines a helical 
hairpin in the Cdc25 domain that undergoes conformational rearrangement when Ras proteins 
bind to the Cdc25 domain. These rearrangements break bonding contacts between the REM and 
Cdc25 domain revealing two hydrophobic patches, one in each domain, creating an allosteric 
binding site for Ras-GTP. Thus, Sos proteins bind Ras with a 2:1 stoichiometry. Importantly, 
when Ras-GTP binds at the allosteric site, nucleotide exchange activity by Sos1 at the primary 
site in the Cdc25 domain is dramatically enhanced. This allosteric mechanism dramatically 
increases the effective concentrations of active Ras as it clusters around receptors at the cell 
surface (PDB: 1NVV, 1NVW, 1XD2, 1XD4, 1XDV). 
Epac subfamily 
There are four isozymes in the subfamily of the Exchange proteins activated by cyclic 
adenosine monophosphate (cAMP), Epac1 and Epac2A, 2B, and 2C. They all have five 
functional domains, although Epac1 have slightly different arrangements in their domain 
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architecture. The N-terminus of Epac1 has a Dishevelled, Egl-10, Pleckstrin (DEP) domain, 
followed by a cyclic nucleotide-binding domain (CNBD), a REM domain, a Ras-associated 
domain (RA), and catalytic Cdc25 domain. Epac 2 isozymes contain an N-terminal high affinity-
CNBD domain, a DEP domain, a second, low affinity-CNBD, a REM domain, a Ras-associated 
domain (RA), and catalytic Cdc25 domain (80). 
Epac isozymes were first discovered in a database search for unique proteins in cells that 
could activate Rap isozymes, downstream of increased concentrations of cAMP. Epac1 and 
Epac2 isozymes are differentially expressed; Epac1 isozymes are most abundant in the heart, 
liver, blood vessels, and adipose tissue. In the heart, Epac1 signals through b1-adrenergic 
receptors and is necessary for cardiac contractility, relaxation, and establishing a consistent heart 
rate (81). However, sustained, elevated levels of cAMP in cardiac myocytes can lead to cardiac 
hypertrophy, and/or heart failure. Epac2 isozymes are expressed in the adrenal glands and 
pancreas (126). Rap1 activation by Epac2 triggers insulin and glucagon secretion in the pancreas 
without which increases the risk of obesity (82, 83). 
Data from crystal structures of Epac2 show that these isozymes remain in an 
autoinhibited state that is released by conformational rearrangements induced by cAMP binding. 
The details about the rearrangements have been described using data from crystal structures 
comparing the conformations of active Epac2 to inactive Epac2 isozymes. Autoinhibition is 
released when cAMP binds to the CNBD and phenylalanine 435 is displaced exposing the 
binding site for Rap isozymes in the Cdc25 domain. F435 is a residue within the fifth helix of the 
N-terminus referred to as the ionic latch and stabilizes Epac2 in a more compact form relative to 
the active protein (PDB: 2BYV) (84, 85). Furthermore, F435G substitution in Epac2 causes 
binding of Rap isozymes in the absence of cAMP (PDB: 3CF6) (86). 
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CHAPTER 4: A NEGATIVE-FEEDBACK LOOP REGULATING ERK1/2 
ACTIVATION AND MEDIATED BY RASGRP2 PHOSPHORYLATION  
Introduction 
The Ras-Raf-MEK-ERK signaling pathway is essential for many cellular processes, 
including growth, cell-cycle progression, differentiation, and apoptosis. ERK1/2 phosphorylates 
hundreds of substrates in vivo, but these activities are restricted by cell type and subcellular 
compartment (87). Furthermore, the complexities and dynamics of ERK1/2 signaling are 
modified by both positive and negative-feedback loops (88). For example, Sos1 is a GEF that 
actives Ras isoforms. In turn, active Ras allosterically enhances the exchange capacity of Sos1 
and this positive feedback loop ultimately impacts ERK1/2 activation (76, 89). Conversely, 
ERK1/2 phosphorylates both Sos1 and Raf to suppress further activation of ERK1/2 in a 
negative-feedback loop (90-92). 
ERK1/2 is also activated downstream of the small GTPase, Rap1, in platelets. (10, 16, 92, 
94). However, in contrast to activation by Ras isoforms, very little is known about potential 
feedback regulation by ERK1/2 on Rap1 signaling. RasGRP2 (alternative name CalDAG-GEFI) 
is the predominant GEF that activates Rap1 in platelets. RasGRP2 specifically activates Rap1 but 
not Ras isoforms both in vitro and in vivo (17, 18). In this study, using purified proteins and 
cellular studies, we show that ERK1/2 phosphorylates RasGRP2 to limit its exchange activity. In 
addition, we show that this connection establishes a negative-feedback loop that ultimately 
controls the dynamics of active ERK1/2.  
93 Ren, J., Cook, A. A., Bergmeier, W., and Sondek, J. (2016) A negative-feedback loop regulating ERK1/2 
activation and mediated by RasGPR2 phosphorylation. Biochemical and Biophysical Research 
Communications. 474, 193–198 
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Results 
ERK2 phosphorylates RasGRP2 at Ser394 in vitro 
RasGRP family members have four conserved functional domains: i) an N-terminal Ras-
exchange motif (REM), ii) a catalytic CDC25 domain, and a C-terminal regulatory region 
comprised of iii) two EF hands and iv) an atypical C1 domain (Fig. 3A). Post-translational 
modifications to RasGRP2 have previously been identified and are available from several 
databases that provide mass spectral data (95, 96). From these databases, we noted that RasGRP2 
is phosphorylated at Ser394 within the linker between the CDC25 domain and EF hands. In 
particular, this region occludes the Ras-binding region of RasGRP1 in its autoinhibited state and 
is conserved in other RasGRP isoforms (54). Furthermore, sequence adjacent to Ser394 matches 
a consensus motif of many ERK1/2 substrates defined by P-X-S/T-P, where “X” indicates any 
amino acid and S/T is the site of phosphorylation (Fig. 3A). Thus, we hypothesized that ERK1/2 
phosphorylates RasGRP2 at Ser394 to potentially regulate its capacity to activate Rap1. 
To test this idea, we initially assessed the capacity of constitutively active ERK2 (ERK2-
CA) to phosphorylate purified RasGRP2. Notably, ERK2-CA robustly phosphorylated RasGRP2 
but not in other proteins including GST, H-Ras and Rap1b (Fig. 3B). Moreover, ERK2-CA failed 
to phosphorylate RasGRP2(S394A) indicating that Ser394 is the major site of phosphorylation 
under these conditions. 
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Figure 3. ERK2 phosphorylates RasGRP2 at Ser394 in vitro 
A. Domain architecture of human RasGRP2. Sequence alignment for the individual 
RasGRP family members highlights the conserved ERK1/2 phosphorylation motif “PXSP” (red) 
in the linker between the Cdc25 domain and the EF hands. Asterisk identifies Ser 394 in 
RasGRP2. B. ERK2 phosphorylates RasGRP2 in vitro. C. ERK2 phosphorylates RasGRP2 at 
Ser394. For panels B and C, bacterially purified proteins (5 µg) were incubated with 
recombinant, constitutively active ERK2 in the presence of (32P) γ-ATP for 10 min prior to SDS-
PAGE and autoradiography
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The ERK1/2 pathway is required for phosphorylation of RasGRP2 in cells 
HEK239T cells are competent to activate ERK1/2 downstream of EGF activation. 
Consequently, we transfected these cells with either WT RasGRP2 or RasGRP2(S394A) prior to 
stimulation with EGF. Without EGF addition, RasGRP2 is basally phosphorylated based on an 
antibody specific for ERK1/2 substrates (Fig. 4A). Consistent with our in vitro data.
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Figure 4. RasGRP2 is phosphorylated in response to epidermal growth factor (EGF) 
stimulation in HEK293T cells. 
A. RasGRP2 is basally phosphorylated at Ser394 in HEK293T cells. Plasmids encoding 
FLAG-tagged RasGRP2 wild-type (WT) or S394A were transfected into HEK293T cells prior to 
immunoprecipitation of the expressed protein and western blotting as indicated. The parental 
vector was used as a control and treated similarly. B Phosphorylation of RasGRP2 in response to 
EGF is eliminated by the MEK inhibitor, U0126. Cells were pretreated with the indicated 
amount of U0126 or DMSO for 1 hr prior to stimulation with 50 ng/ml EGF for 5 min. FLAG-
RasGRP2 was immunoprecipitated from cell lysates and followed by western blotting as 
indicated. Cell lysates were also blotted for total ERK1/2 (T-ERK1/2) and phos-ERK1/2 (P-
ERK1/2)
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However, RasGRP2(S394A) is poorly phosphorylated under these conditions. Upon stimulation 
with EGF, phosphorylation of RasGRP2 is increased and conversely, this phosphorylation is 
dramatically decreased upon inhibition of MEK1 with the small molecule, U0126 (Fig. 4B).  
Phospho-mimetic mutation of RasGRP2 impairs nucleotide exchange activity 
A fluorescence-based, guanine nucleotide exchange assay was used to assess the capacities of 
purified RasGRP2 proteins to activate Rap1b (Fig. 5A-B). The intrinsic rate of nucleotide 
exchange of Rap1b is low and this rate was increased dramatically by the addition of RasGRP2. 
A similar increase in exchange activity was seen upon addition of RasGRP2(S394A). However, 
the phospho-mimetic mutant, RasGRP(S394E), was unable to activate Rap1b to the same degree. 
Consistent with these in vitro findings, the expression of RasGRP2(S394E) in cells led to 
reduced levels of active Rap1 when compared to cells expressing RasGRP2 or RasGRP2(S394A) 
(Fig. 5C-D). 
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Figure. 5. Phosphorylation of RasGRP2 impairs its nucleotide exchange activity 
A. Purified proteins (3 µg) were subjected to SDS-PAGE and stained with Coomassie 
Brilliant Blue. B. In vitro nucleotide exchange assay. Equivalent amounts of Rap1b and 
BODIPY-FL-GDP were preincubated prior to the addition (arrow) of the indicated forms of 
RasGRP2. C. GST-RalGDS was used to precipitate GTP-Rap1 from HEK293T cells expressing 
the indicated forms of RasGRP2 prior to western blotting for proteins as indicated. D. GTP-Rap1 
levels as shown in C were normalized to that of WT (average ± SEM).
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RasGRP2 phosphorylation negatively regulates ERK1/2 activation 
ERK1/2 activation by Rap1 requires B-Raf (10). The previous experiments indicate that 
ERK1/2 phosphorylates and inhibits the Rap1 GEF, RasGRP2. Thus, it is possible that these 
proteins participate in a negative-feedback loop whereby active ERK1/2 leads to decreased 
active Rap1 through RasGRP2. Since HEK293T cells also express B-Raf in addition to being 
competent to activate ERK1/2 as shown above, we used this cell line to delineate potential 
linkages between RasGRP2 and ERK1/2. Consistent with a negative-feedback loop, expression 
of RasGRP2(S394A), which is not able to be phosphorylated, increased levels of phos-ERK1/2. 
(Fig. 6A-B). Expression of the phospho-mimetic mutant, RasGPR2(S394E), did not substantially 
reduce phos-ERK1/2 levels, but this situation might arise due to the already high basal levels of 
phosphorylated WT RasGRP2 in these cells (Fig.6). 
Studies show disruption of other ERK1/2 negative-feedback loops increase the amplitude 
and duration of ERK1/2 activation upon stimulation (3). If phosphorylation of RasGRP2 at 
Ser394 is critical for a negative-feedback loop involving active ERK1/2, then we might expect to 
see an increase in the amplitude and duration of ERK1/2 activation upon expression of 
RasGRP2(S394A). Indeed, ERK1/2 activation was increased and prolonged in EGF-stimulated 
cells expressing RasGRP2(S394A) when compared to cells expressing WT RasGRP2 (Fig. 6C).
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Figure 6. Phosphorylation of RasGRP2 negatively regulates ERK1/2 
A. P-ERK1/2 levels in HEK293T cells transfected with the indicated forms of RasGRP2. 
Cells were lysed 24 hrs after transfection and analyzed by western blotting as indicated. B. 
Levels of P-ERK1/2 as shown in A for three independent experiments (average ± SEM), 
analyzed with Image J and normalized to that of the cells transfected with WT RasGRP2. C. 
RasGRP2(S394A) increases the magnitude and duration of ERK1/2 phosphorylation in response 
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to EGF stimulation. HEK293T cells were transfected with either WT or mutant RasGRP2. 
Twenty-four hours after transfection, cells were starved for 2 hours and treated with 20 ng/ml 
EGF for the indicated times prior to lysis. Cell extracts were subjected to SDS-PAGE and 
immunoblotting as indicated. The result is representative of three independent experiments. (D) 
Model of the RasGRP2 mediated negative-feedback loop. Active EGFR recruits and activates 
PLC-g isozymes leading to elevated levels of intracellular calcium and subsequent activation of 
RasGRP2. Activated RasGRP2 catalyzes the formation of GTP-bound Rap1 to initiate signaling 
through B-Raf to ERK1/2. ERK1/2 subsequently phosphorylates RasGRP2 at Ser394 to impair 
the activation of Rap1 and ultimately attenuating the Rap1-ERK pathway.  
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Discussion 
The equivalent of Ser394 and surrounding residues of RasGRP2 are conserved in all 
members of the RasGRP family suggesting that the negative-feedback loop described here for 
RasGRP2 is also relevant for signaling by other RasGRP family members. Consistent with this 
hypothesis, phosphorylation of human RasGRP3 at Ser391, the equivalent of Ser394 in 
RasGRP2, was identified in two independent phosphoproteomics studies (97, 98).  
In addition to ERK1/2, PKA has also been shown to phosphorylate RasGRP2 at multiple 
sites (99-101). However, these studies have produced conflicting results. In the original studies, 
phosphorylation by PKA resulted in the inhibition of RasGRP2 in HEK293T cells, while the 
most recent study showed PKA-mediated activation of RasGRP2 in Cos-7 cells. It is difficult to 
reconcile these results and perhaps future studies using purified proteins will clarify this issue. It 
seems likely that the RasGRP proteins are directly targeted by diverse kinases and that the 
regulation of RasGRP2 by phosphorylation is crucial for a range of cellular processes.  
Signaling cascades leading to the activation of ERK1/2 are subject to stringent 
homoeostatic control through both positive and negative-feedback loops. A number of inhibitors 
that target these cascades are used to treat cancer. However, drug-resistant tumors frequently 
emerge leading to disease progression. Alteration in the feedback regulation of ERK1/2 pathway 
is one potential cause of acquired drug resistance. Our study has defined a new negative-
feedback loop from ERK1/2 to RasGRP2 and this feedback contributes to the dynamic 
regulation of ERK1/2 activity that likely has clinical ramifications.
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CHAPTER 5: CALCIUM-INDUCED STRUCTURAL 
REARRANGEMENTS RELEASE AUTOINHIBITION IN THE RAP-GEF, 
CALDAG-GEFI 
Introduction 
Human survival depends on our ability to prevent blood loss at sites of vascular injury. 
Upon damage to the endothelial lining, blood platelets detect exposed extracellular matrix and 
locally produced thrombin, become activated, and form a hemostatic plug. Critical to plug 
formation is the engagement of the aIIbb3 integrins on the cell surface, a process that depends 
on the inside-out signaling to these receptors (4). 
 Given the unique high shear environment found in blood vessels, the signal transduction 
in platelets leading to integrin inside-out activation has been optimized for sensitivity and speed. 
Upon receptor stimulation, the second messenger calcium, is rapidly released from the dense 
tubule system (DTS). Calcium also enters through channels in the plasma membrane, effectively 
increasing intracellular calcium concentrations 50-fold. Calcium plays an important role in the 
activation of aIIbb3. Integrin activation also depends strongly on the focal adhesion proteins, 
talin-1 and kindlin-3, as well as the small GTPase Ras-related protein (Rap) 1 (2, 4). The Rap1 
isozymes, Rap1A and Rap1B, are guanine nucleotide binding proteins and members of the large 
superfamily of Ras small GTPases. Small GTPases act like molecular switches, cycling between 
an inactive, GDP-bound, and an active, GTP-bound, state. The biological role of Rap1B in 
platelets has been well studied. Genetically modified mice lacking the Rap1B isozyme have a 
102 Cook, A. A., Deng, W., Ren, J., Li, R., Sondek, J., and Bergmeier, W. (2018) Calcium- 
induced structural rearrangements release autoinhibition in the Rap-GEF, CalDAG-GEFI. J.  
Biol. Chem. 10.1074/jbc.RA118.002712 
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number of platelet defects, including a marked reduction in integrin activation in response to 
agonist stimulation (1). 
Small GTPase activity is modulated by guanine nucleotide exchange factors (GEFs) and 
GTPase-activating proteins (GAPs). The most abundant Rap-GEF and Rap-GAP in platelets are 
calcium- and diacylglycerol-regulated guanine nucleotide exchange factor I, (CalDAG-GEFI, 
RasGRP2) and Ras p21 protein activator 3, (RASA3, GAP1IP4bp), respectively (17, 40). 
CalDAG-GEFI contains a Ras exchange motif (REM) domain with no known function, a 
catalytic Cdc25 domain, a pair of calcium binding EF hands, and an atypical C1 domain with no 
known function. Studies in mice, dogs, and humans lacking functional CalDAG-GEFI, 
demonstrate that CalDAG-GEFI/Rap1B signaling is crucial for rapid activation of aIIbb3 
required for platelet adhesion at sites of vascular injury (17, 103-105). 
EF hands are composed of pairs of helices that typically bind calcium using acid residues 
within the intervening loop. These residues are defined by their relative positions (1, 3, 5, and 
12) and in particular position 12 is a highly conserved glutamate that coordinates calcium 
through bidentate interactions. Mutating this glutamate cripples calcium binding (51, 56). 
Calcium binding generally leads to major conformational changes in the EF hands and other 
regions of the protein (53). 
Our functional studies in platelets suggested calcium is involved the regulation of 
CalDAG-GEFI activity (10). In this work, we present biochemical evidence that both EF hands 
contribute to CalDAG-GEFI activation and that activity require calcium. Hydrogen-deuterium 
exchange mass spectrometry studies further suggest that calcium binding induces global 
conformational changes within CalDAG-GEFI, most prominently in the EF hands and a putative 
autoinhibitory linker sequence connecting the EF hands and Cdc25 domain. Analysis of different 
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mutant forms of CalDAG-GEFI confirms the linker is important for autoinhibiting CalDAG-
GEFI in the absence of calcium. Thus, our work provides the first evidence that (1) CalDAG-
GEFI activity is directly regulated by calcium and (2) release of autoinhibition as the molecular 
mechanism underlying CalDAG-GEFI activation.  
Results 
CalDAG-GEFI activation is calcium-dependent.  
Previous studies using isothermal titration calorimetry determined the isolated EF hands 
of CalDAG-GEFI (amino acid residues 417-495) bind calcium with very high affinity (Kd~80 
nM) (54). To determine if calcium affects catalytic activity in full length CalDAG-GEFI, we 
established a cell-free nucleotide exchange assay using purified human CalDAG-GEFI and 
Rap1B proteins. Purified CalDAG-GEFI (amino acid residues 1-551, WT) was slightly truncated 
at the C-terminus to increase protein stability. Rap1B (amino acid residues 1-181) was purified 
with a substitution, cysteine 181 to serine, to increase solubility (Fig. 7A). Purification was 
performed using affinity and size exclusion chromatography. Proteins were >95% pure as 
confirmed by SDS-PAGE (Fig. 1B, inset). Proteins were stable at 4˚C for up to 15 hours. 
Compared to Rap1B alone, exchange activity increased by ~16-fold in samples containing 
Rap1B and CalDAG-GEFI. Of note, exchange activity was not altered by the addition of free 
calcium (not shown). However, treatment of CalDAG-GEFI with a 20mM ethylene glycol-bis 
(β-aminoethyl ether)-N, N, N', N'-tetraacetic acid (EGTA), a calcium-selective chelator, 
dramatically reduced catalytic activity. Importantly, exchange activity was restored upon 
addition of 10 mM free calcium, demonstrating that the loss of activity in EGTA-treated samples 
was not due to protein instability (Fig. 7B). 
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Figure 7. CalDAG-GEFI requires calcium to activate Rap1B. 
 A. Domain architecture. Rap1B is primarily composed of a Ras-like domain (red) while 
CalDAG-GEFI is a multi-domain protein consisting of a Ras exchange motif (REM) domain 
(salmon), catalytic Cdc25 domain (green), a putative autoinhibitory linker (red), two calcium-
binding EF hands (blue), and an atypical C1 domain (yellow). CalDAG-GEFI was truncated 
(dotted lines) at residue 551 for purification. Truncated residues are not conserved and do not 
impact the capacity of CalDAG-GEFI to activate Rap1B. Substitutions in CalDAG-GEFI used in 
this paper are marked (red circles) below its domain architecture. B. Activation of Rap1B by 
CalDAG-GEFI monitored by the increased fluorescence of BODIPY FL GDP loaded onto 
Rap1B. Nucleotide (100 nM) and GTPase (1 µM) were incubated in four wells monitored 
simultaneously (lex/em = 480/520). Select reactions also included 10 mM EGTA as indicated. At 
12 min (left arrow), 400 nM CalDAG-GEFI was added to all reactions except the one marked 
“Rap1B alone”. Addition of 10 mM free Ca2+ (right arrow) reconstituted exchange activity. 
Inset: purified CalDAG-GEFI and Rap1B (2 µg) used in nucleotide exchange reactions; stained 
gel after SDS-PAGE.
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Both EF hands are critical for regulating CalDAG-GEFI exchange activity.  
To determine if and how the individual EF hands regulate CalDAG-GEFI activity, we 
mutated a key residue in the calcium binding loops (Fig. 8A). Substitutions of glutamic acid at 
position 12 in the calcium binding loop of EF hands has been shown to reduce the binding 
affinity for calcium by over 100-fold (106, 107). Glutamic acid substitution for alanine at 
position 450 in the N-terminal EF hand (EF1) or position 479 in the C-terminal EF hand (EF2) 
markedly decreased nucleotide exchange towards Rap1B. Catalytic activity was restored by 
adding increasing concentrations of calcium in EF2, while only a partial recovery was observed 
in the EF1. Catalytic activity in the double EF hand mutant (EF1+2) could not be restored (Fig. 
8A). These data provide strong evidence that calcium binding to EF1 is essential for exchange 
activity in CalDAG-GEFI, while EF2 is important but not essential in this process. To validate 
our in vitro findings in a cellular context, we studied agonist-induced Rap1 activation in 
HEK293T cells expressing WT or EF1+2 CalDAG-GEFI (Figure 8B). Cellular stimulation with 
epidermal growth factor (EGF) led to a significant increase in Rap1-GTP levels in cells 
expressing WT CalDAG-GEFI. In contrast, Rap1 activation was not observed in EGF-stimulated 
cells expressing EF1+2 CalDAG-GEFI.  
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Figure 8. Mutations in the calcium-binding EF hands reduce the capacity of CalDAG-
GEFI to active Rap1B. 
A. Nucleotide exchange was monitored as described in Figure 1. EF1 and EF2 indicate 
mutant forms of CalDAG-GEFI substituted (E450A and E479A) at equivalent positions within 
the N- and C-terminal EF hands, respectively; EF1+2 indicates the double mutant. Insets: stained 
gels of purified, mutants of CalDAG-GEFI (2 µg) after SDS-PAGE. B., left panel: stained gel for 
GST-RBD pull down of active Rap1B from HEK-293T cells expressing WT or EF1+2 proteins 
after SDS-PAGE and Western blot analysis. Right panel (representative of three independent 
experiments). Cells were incubated for 5 minutes in the presence and absence of 100ng/ml 
epidermal growth factor (EGF) before lysis. Right panel: Quantification of Rap1-GTP levels 
(mean± SD). 
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Calcium binding to CalDAG-GEFI induces conformational rearrangements required for 
its activity.  
We next performed hydrogen-deuterium exchange mass spectrometry experiments 
(HDX-MS) to determine the differences in deuterium uptake between WT and EF1+2 proteins. 
Measuring the rate of deuterium uptake defines the stability of hydrogen bond networks between 
residues stabilizing secondary structure in proteins as well as residues that are more solvent 
accessible (108, 109). The most stable hydrogen bonds have the slowest exchange while more 
dynamic regions exchange faster. WT and EF1+2 proteins were exposed to deuterated water for 
a designated amount of time and then quenched and digested for mass spectrometric analysis. 
We recovered 326 peptides from the WT sample and 329 from the EF1+2 sample, with complete 
coverage of both samples.  
The relative difference in deuterium uptake was represented in a heat map to highlight the 
regions with slowest (dark blue) and fastest (red) deuterium exchange (Fig. 9A). WT and EF1+2 
showed unique deuterium exchange signatures, suggesting conformational differences between 
the active and the apo form of the protein. A greater than 5% difference in uptake between two 
samples is considered significant (109). Deuterium uptake in a putative autoinhibitory region 
linking the Cdc25 domain and EF1 was markedly higher in the WT sample (23% and 25%, 
respectively) (Fig. 9A). Different regions of the WT sample had greater than 12% higher rates of 
exchange in WT compared to EF1+2 (Fig. 9B), including a small portion of the REM domain 
(19%), the Cdc25-Rap1B interface (20%), and the EF hands (17%) Displacement of the linker in 
response to calcium binding would provide a likely explanation for the very fast deuterium 
exchange rates measured for the residues comprising the Cdc25 domain-Rap1B interface in the 
WT protein.  
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Figure 9. Differential hydrogen-deuterium exchange between CalDAG-GEFI WT and 
EF1+2.  
A. Heat maps of deuterium uptake for CalDAG-GEFI and EF1+2. Proteins were 
incubated in deuterated water for indicated times prior to measurements of deuterium uptake 
using mass spectrometry. Largest differences in uptake between the two proteins span the 
putative autoinhibitory linker and EF hands shown for individual peptides below the heat maps. 
B. Homology model of CalDAG-GEFI. Blue regions map enhanced deuterium uptake (> 12%; 
excluding the linker) of CalDAG-GEFI relative to EF1+2. The majority of these regions cluster 
within the binding site for Rap1B and EF hands shown in expanded views
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Valine 406 contributes to maintain CalDAG-GEFI in an autoinhibited state.  
We next determined critical residues within the putative autoinhibitory linker region 
using a homology model of inactive CalDAG-GEFI, based on predictions by the Iterative 
Threading ASSembly Refinement (I-TASSER) server (for more details see Material and 
Methods section) (https://zhanglab.ccmb.med.umich.edu/I-TASSER/). We identified amino 
acids 406-410 (VLEEW) as the residues that insert directly into the Rap1B binding groove (Fig. 
10A, B). This region of the linker is fully conserved in all mammals. To test whether 
displacement of this linker is sufficient to activate CalDAG-GEFI, we purified both WT and 
EF1+2 protein with an additional substitution, a valine 406 for glutamic acid and tested the 
capacity of these proteins for nucleotide exchange towards Rap1B. We selected to substitute 
valine 406 as our homology model suggested a key role for this residue in anchoring the 
autoinhibitory linker in the Rap1 binding groove. Consistent with this conclusion, the V406E 
mutation completely restored catalytic activity in EF1+2 CalDAG-GEFI, suggesting that the 
autoinhibitory linker was displaced in this mutant in absence of bound calcium (Fig. 10C). The 
V406E mutation had a weaker effect in the WT protein, where nucleotide exchange activity was 
still markedly impaired in the presence of EGTA (Fig. 10D). These studies suggest that the 
interaction of V406 with the Cdc25 domain contributes to the autoinhibited state of CalDAG-
GEFI. 
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Figure 10. Substitution of a conserved valine fully restores the exchange activity of EF1+2.  
A. Homology model of CalDAG-GEFI with putative autoinhibitory linker highlighted in 
red. B. Equivalent homology model with linker removed and Rap1B docked onto the structure. 
C. Substitution of valine 406 (V406E) fully restores the exchange capacity of EF1+2. Inset: 
stained gel of purified EF1+2+V406E after SDS-PAGE. D, Exchange activity of CalDAG-GEFI 
WT+V406E, both in the presence and absence of EGTA and exogenous calcium. Inset: stained 
gel of purified WT+V406E after SDS-PAGE.
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Discussion 
The four members of the CalDAG-GEF (RasGRP) family are critical for the proper 
function of different blood cell types (94). They all possess a characteristic domain structure with 
an N-terminal REM/Cdc25 catalytic domain and a C-terminal regulatory domain consistent of a 
pair of EF hands and a C1 domain. In this work, we investigated the mechanistic details by 
which calcium affects nucleotide exchange activity in CalDAG-GEFI, a key regulator of Rap1 
signaling in platelets. Compared to CalDAG-GEFII (RasGRP1), the best studied family member, 
CalDAG-GEFI shows significant differences in the Cdc25 catalytic domain and the EF hand and 
C1 regulatory domains. CalDAG-GEFII is a RasGEF that exists as a dimer in solution. Binding 
of diacylglycerol (DAG) to its C1 domain is critical for dimer release and thus CalDAG-GEFII 
function. In contrast, CalDAG-GEFI is primarily a Rap-GEF, does not dimerize, and does not 
contain a typical, DAG binding C1 domain. There are also significant differences with regard to 
the EF hand regulatory domain; while CalDAG-GEFII contains only one active, low affinity 
(KD > 1uM) EF hand, CalDAG-GEFI contains two fully functional EF hands with high affinity 
for calcium (KD < 100nM) (54). The high affinity for calcium is consistent with the documented 
role of CalDAG-GEFI in the rapid, calcium-dependent activation of Rap1 and integrin aIIbb3 
that is required for platelet adhesion under shear stress conditions (10). Using biochemical and 
biophysical approaches, we demonstrate that both EF hands are critical for CalDAG-GEFI 
function and we provide evidence that calcium binding induces global conformational changes in 
CalDAG-GEFI, most prominently in an autoinhibitory linker region that prevents Rap1 binding 
to the Cdc25 domain in absence of calcium.  
Our data suggest a straightforward model for the regulation of CalDAG-GEFI exchange 
activity (Fig. 5). In circulating platelets with low intracellular levels of calcium, CalDAG-GEFI 
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is in an autoinhibited state stabilized by the linker region between the Cdc25 domain and the EF 
hands. This linker blocks the catalytic surface of the Cdc25 domain so that it cannot engage 
Rap1B. Upon an external stimulus that raises intracellular levels of calcium, the EF hands bind 
calcium and change conformation. These conformational changes are coupled to movement of 
the autoinhibitory linker that reveals the catalytic surface needed to engage Rap1B. After Rap1B 
binding and GTP for GDP exchange, the complex dissociates freeing GTP-bound Rap1B to 
engage downstream effectors (Figure 11). 
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Figure 11. Model for calcium-dependent rearrangements within CalDAG-GEFI required 
for its engagement and activation of Rap1B 
At low concentrations of intracellular calcium (left), the linker encompassing valine 406 
blocks the surface of the Cdc25 domain that engages Rap1B. As calcium levels rise (right), the 
EF hands bind calcium and change conformation. This rearrangement moves the linker, 
liberating the surface of CalDAG-GEFI needed to bind Rap1B.
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Based on isothermal titration calorimetry experiments, the individual EF hands of 
CalDAG-GEFI bind one calcium ion with high affinity (Kd ~ 80 nM) (54). This result strongly 
suggests that the two EF hand domains may act in concert to activate CalDAG-GEFI. Indeed, 
disabling either EF hand markedly impaired the exchange activity. Addition of free calcium in a 
dose-dependent manner restored exchange activity in the EF2 mutant. In contrast, only a partial 
recovery of function was observed for the EF1 mutant. Disabling both EF hands in CalDAG-
GEFI rendered CalDAG-GEFI unresponsive to calcium. These studies suggest that EF2 is 
critical for high affinity calcium binding, while EF1 is important for inducing conformational 
changes required for CalDAG-GEFI catalytic activity.  
Regulating activity via high affinity binding to calcium explains perfectly why CalDAG-
GEFI plays such a crucial role in platelet function. Platelets circulate at high velocity in the 
blood stream, patrolling the vasculature for breaches in the endothelial lining. To fulfill their 
hemostatic function, platelets need to be able to sense minute changes in their environment and 
to rapidly change from an anti-adhesive to a pro-adhesive state. Even weak platelet agonists such 
as ADP cause rapid and significant changes in cytoplasmic calcium. CalDAG-GEFI can quickly 
integrate this calcium signal and mediate a near-immediate activation of Rap1 and aIIbb3 
integrin. 
However, such high sensitivity to calcium, also poses a challenge, as unwanted CalDAG-
GEFI activation could lead to premature platelet activation and thrombosis. In fact, one would 
expect that, if CalDAG-GEFI binds calcium at such high affinity, a large pool of CalDAG-GEFI 
would be activated in resting, circulating platelets. Thus, additional regulatory mechanisms must 
be in play to prevent unwanted platelet activation. One important mechanism that would offset 
CalDAG-GEFI signals is via negative regulation by RASA3, a Rap-GAP highly expressed in the 
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platelet membrane. In mice, loss of RASA3 function leads to platelet pre-activation, rapid 
platelet clearance and severe thrombocytopenia due to unbalanced CalDAG-GEFI signaling (40). 
It is also possible that CalDAG-GEFI function depends on more than just calcium 
binding to its EF hands. For example, the C1-like domain may provide additional regulatory 
activity. Within the CalDAG-GEF family, CalDAG-GEFI is the only member that contains an 
atypical C1 domain with very low affinity for diacylglycerol (Kd ~ 2 µM vs. Kd ~ 5 nM for the 
other family members) (64). Structural studies by Iwig et al. demonstrated that DAG binding to 
the C1 domain in CalDAG-GEFII is important to release C1 domain dimerization, causing 
protein translocation to the membrane (54). In contrast, CalDAG-GEFI is a monomer, and 
platelets lacking CalDAG-GEFI aggregate normally in response to stimulation with phorbol ester 
(17), a DAG mimetic that engages typical C1 domains. However, platelets expressing a truncated 
CalDAG-GEFI, lacking the C1 domain, are defective in their integrin activation and aggregation 
responses (36). Thus, the C1 domain clearly plays a role in CalDAG-GEFI function, but further 
studies will be required to unravel the underlying molecular mechanism(s). 
The comparison of hydrogen-deuterium exchange profiles for active (wild-type) and 
inactive (EF1+2) CalDAG-GEFI provides important structural insights on how GEF activity is 
regulated by binding of calcium. Central to this regulation are the autoinhibitory linker and the 
EF hands. The autoinhibitory linker is bracketed by residues with some of the largest deuterium 
uptake differentials between the active and crippled forms of CalDAG-GEFI. Furthermore, the 
regions of the Cdc25 domain critical for GEF activity, based on the homology model, also 
showed markedly increased deuterium uptake in the active protein when compared to the EF1+2 
mutant. These differences support the contention that the autoinhibitory linker moves away from 
the catalytic surface of the Cdc25 domain upon engagement of the EF hands by calcium. The 
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fact that substitution of valine 406, centered within the autoinhibitory linker, is sufficient to fully 
rescue the exchange capacity of the EF1+2 mutant strongly supports our interpretation of the 
HDX data. Our studies with the WT V406E mutant further suggest that residues in the vicinity of 
valine 406 contribute to stabilizing the autoinhibitory linker in the Rap1 binding groove. At this 
point, we can only speculate why the EF1+2 mutant is more sensitive to the introduction of the 
V406E mutant. We observed that, in the presence of EGTA, the EF1+2 mutant has a much 
higher exchange activity relative to the WT protein (not shown). This finding may suggest that 
the point mutations in the EF hands have a minimal effect on the structure of the protein, slightly 
increasing exchange activity. Introduction of the V406E mutation then shifts the protein into a 
conformation that allows full activity in our cell-free assay. In the WT protein, introduction of 
the V406E mutation has a milder effect. 
It is interesting that additional regions of CalDAG-GEFI also exhibit differential 
hydrogen-deuterium exchange. These regions include portions of the REM domain, the region 
between REM and Cdc25 domains, and portions of the C1 domain. Presumably, the calcium-
dependent activation of CalDAG-GEFI is initiated by structural alterations within the EF hands, 
but these alterations consequently propagate throughout the protein. The functional impact of 
these additional alterations should be determined in future work, as there is precedent in Sos1 
that the REM and Cdc25 domains cooperate to activate Ras GTPase (76). Intriguingly, the 
autoinhibitory linker might be expected to contain the highest differences in hydrogen-deuterium 
exchange based on the proposed model. However, this is not the case, suggesting that it is not 
completely disordered upon calcium-dependent activation. Instead, it seems likely that this 
region adopts an alternative, stable conformation upon calcium binding perhaps interacting with 
the EF hands themselves. 
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Taken together, our data provide mechanistic insight on the functional consequences of 
calcium binding to the EF hands of CalDAG-GEFI and the structural rearrangements required 
for GEF activity to occur. These findings will be important in our understanding of how 
mutations in patients impair CalDAG-GEFI function and in efforts to design inhibitors of 
CalDAG-GEFI signaling. 
Experimental procedures 
Reagents. HRP-conjugated secondary antibodies, His-trap HP affinity, and size exclusion 
columns were purchased from GE Healthcare, Marlborough, MA. FLAG M2 (catalog no. F3165-
.2MG) monoclonal antibody purchased from Sigma-Aldrich (St. Louis, MO). Epidermal growth 
factor (EGF) (catalog no. E9644), GDP-BODIPY (catalog no. G22360), and EGTA (catalog no. 
E1219) were purchased from Gibco/Thermo Fisher Scientific, Waltham, MA. 
Protein purification.  
A plasmid containing the gene coding for human CalDAG-GEFI was purchased from 
Harvard University's Human ORFeome v5.1. The gene was PCR-amplified using primers 
introducing a stop at position 1653 in the nucleotide sequence. The cDNA was subcloned into a 
p15LIC2 bacterial expression vector. The expressed protein, CalDAG-GEFI (1-551), contained 
all functional domains plus an N-terminal 6x histidine tag required for purification. Cloning was 
performed according to ligation-independent cloning protocol. CalDAG-GEFI (1-551) EF hand 
mutant (EF1) was made by substituting glutamic acid to alanine at position 450. The EF hand 
mutant (EF2) was made by substituting glutamic acid to alanine at position 479. The EF hand 
double mutant (EF1+2) was made by substituting glutamic acid to alanine at positions 450 and 
479. The EF hand, linker mutant (EF1+2+V406) was made by substituting valine to glutamic 
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acid at position 406 using EF1+2 cDNA for PCR template. All mutations were carried out using 
Quikchange site-directed mutagenesis kit (Stratagene) following the manufacturer’s protocol. 
CalDAG-GEFI proteins were expressed in a Rosetta strain of Escherichia coli (E. coli) 
(Novagen). Cell cultures were grown at 37°C in Lysogeny broth, (LB), 0.5 µM ZnSO4, 50 µg/ml 
ampicillin and chloramphenicol. Protein expression was induced by 500 µM isopropyl  -D-1-
thiogalactopyranoside then incubated for 15 hours at 20°C. Cell pellets were resuspended in 20 
mM PIPES pH 6.8, 300 mM NaCl, 0.5 µM ZnSO4, 10 mM b-mercaptoethanol, 10 mM 
imidazole, 5% glycerol, and 1x protease-inhibitors (Roche). Cell pellets were lysed using 
Emulsiflex C5 cell homogenizer (Avestin) and clarified by ultracentrifugation at 45,000 rpm for 
45 minutes at 4°C. Filtered supernatant was applied to Hi-Trap HP affinity column (GE 
healthcare) equilibrated with buffer A (20 mM PIPES pH 6.8, 300 mM NaCl, 8 mM imidazole, 
and 5% glycerol). Protein was eluted from the column with 400 mM imidazole using buffer B 
(20 mM PIPES pH 6.8, 300 mM NaCl, 1M imidazole, and 5% glycerol). Peak fractions were 
collected and treated with Tobacco etch virus (TEV) protease overnight at 4°C and dialyzed in 
buffer A, less imidazole. A second pass over the His-Trap HP affinity column removed the 
cleaved His-tag and TEV protease from the sample. Flow-through fractions were concentrated 
using vivaspin column (Sartoris) with a 10,000 molecular weight cutoff filter then loaded onto 
Superdex 200 10/300 size exclusion column (GE Healthcare) equilibrated with S200 size 
exclusion buffer containing 20 mM PIPES pH 6.8, 300 mM NaCl, and 4 mM DTT. Final protein 
product was 95% pure, monomeric and concentrated to 20 mg/ml. Aliquots were flash frozen in 
liquid nitrogen and stored at -80°C. 
Human Rap1B (1-181) C181S was cloned into pProEXHtb vector and purified from E. 
coli. 500 µM isopropyl b-D-1-thiogalactopyranoside was used to induce protein expression and 
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cultures were incubated for 8 hours at 20°C. Protein purification was done using the same 
chromatography steps as CalDAG-GEFI proteins listed above with buffer modifications 
substituting the PIPES buffer with Tri-HCl pH 7.0, 1 µM ZnSO4 with 5 mM MgCl2 and adding 
50 µM GDP to protein lysis buffer.  
Nucleotide exchange assay.  
Nucleotide exchange on Rap1B was measured using a fluorescence-based assay as 
previously described (93). Reaction volume was 100 µl containing 1 µM of Rap1B, between 
300-500 nM CalDAG-GEFI, and 100 nM BODIPY-GDP (life technologies). Reaction buffer 
contained 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 5% glycerol, and 
0.004% NP-40. Reactions were performed in a black bottom 96 well plate (Corning). Fluorescent 
signal was measured using a Pherastar microplate reader (BMG LABTECH). (Wavelength 
excitation/emission = 480/520 nm, and 1 nm slits). For calcium chelation experiments, 100 µM 
CalDAG-GEFI was treated with 10 mM EGTA for 2 hours at 4˚C. Sample was spun at 4,000 
RPM for 30 seconds then transferred to a new tube containing reaction buffer, diluting calcium-
free CalDAG-GEFI to 400 nM. Samples were treated with 10 mM calcium where indicated. 
Rap1B pull down assays. Rap1B pull-down experiments were performed as described recently 
(10). 
Hydrogen-deuterium exchange mass spectrometry (HDX-MS).  
HDX-MS experiments on WT CalDAG-GEFI and EF1+2 were performed using a Waters 
UPLC HDX system coupled with a Q-Tof Premier mass spectrometer (Waters Corp, Milford, 
MA) as previously described (110). Briefly, each protein sample was buffer-exchanged into PBS 
then diluted to 1.5 mg/ml. 1µl of sample was diluted 1:7 (v/v) in 10 mM phosphate, 99.9 % D2O, 
pD 7.0 at 20˚C using a robotic autosampler to initiate hydrogen-deuterium exchange. Exchange 
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reactions were quenched after 0.01, 0.15, 1.6, 16, and 166 minutes by placing them at 1˚C and 
adding equal volume of pre-cooled quenching buffer (100 mM phosphate, 0.5 M TCEP, 0.8% 
formic acid, 2% acetonitrile, pH 2.5) Each sample and each time point were done in replicates of 
six. Samples from each time point were fragmented through a Waters Enzymate BEH pepsin 
column, and the peptic fragments were separated on an in-line C18 HPLC column then analyzed 
by mass spectrometry. Mass assignment for each peptide without HDX was inspected manually; 
any assignment with a mass deviation >0.2 Da was removed. The extent of deuterium 
incorporation in each peptide was calculated and tabulated using the Waters software. The 
relative fractional deuterium uptake was represented as a heat map and is measured for each 
peptide by calculating the number of residues that exchange an amide proton for deuterium over 
the total number of protons that are able to exchange (peptide length -1) and averaged for each 
time point. 
Homology model.  
The homology model of CalDAG-GEFI was built using the Iterative Threading 
ASSembly Refinement, (I-TASSER) server available to academic researchers through the Zhang 
Lab at The University of Michigan, (https://zhanglab.ccmb.med.umich.edu/I-TASSER/). I-
TASSER generated our model by comparing the protein sequence of CalDAG-GEFI to protein 
sequences of all proteins that have crystal or CryoEM structures deposited in the Protein Data 
Bank, (PDB). These structures were used as templates to predict secondary structures in 
CalDAG-GEFI based on sequence homology to the template sequence. I-TASSER predicted five 
homology models of CalDAG-GEFI ranked in order from highest to lowest probability; we 
chose the highest probable model. 
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CHAPTER 6: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
Activated receptors on the surface of platelets bind ligands and transmit signals across the 
membrane to activate proteins at the inner leaflet. Regulating intracellular proteins and the 
signals transmitted by these activated proteins requires three events: 1) activated proteins directly 
bind to effector proteins, 2) the activities of effector proteins are altered, and 3) the activities of 
proteins and effectors return to their basal level. The temporal and spatial regulation of proteins 
involved in signaling pathways are often difficult to determine. Biochemical data from 
experiments using isolated platelets can depict regulation of their intracellular proteins as simple, 
binary interactions between proteins in a linear path, and can be misleading. 
These studies determined how the activity of CalDAG-GEFI is regulated in platelets. Our 
studies were based on biochemical data from previous work which showed that: a) CalDAG-
GEFI proteins become active when the intracellular calcium concentration in platelets increases, 
b) CalDAG-GEFI is required to activate Rap isozymes, and c) Rap isozymes are required for 
platelet adhesion (1, 2, 111). To define the biochemical role of calcium for CalDAG-GEFI we 
used purified, full length CalDAG-GEFI and Rap1B proteins in a nucleotide exchange assay to 
measure the activation of Rap1B by CalDAG-GEFI, recapitulating physiological fluctuations in 
calcium concentrations measured in platelets and by mutational analysis to determine specific 
residues in CalDAG-GEFI coupled to its activity. Hydrogen-deuterium exchange mass 
spectrometry (HDX-MS) experiments strangle suggest that calcium binding to the EF hands in 
CalDAG-GEFI induces long-range conformational rearrangements including the Cdc25 domain, 
auto-inhibitory linker, and EF hands.  
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Serendipitously, while working out the mechanistic details for how calcium regulates 
CalDAG-GEFI, multiple independent groups identified patients with an idiopathic bleeding 
phenotype due to mutations in CalDAG-GEFI (105, 112). Not surprisingly, many of them occur 
in the catalytic Cdc25 domain leaving little doubt about their effect on the ability for CalDAG-
GEFI to interact with Rap1B. For two of the mutations identified, we purified those proteins and 
tested their activity toward Rap1B. We determined that the S341F mutation destabilized 
CalDAG-GEFI based on chromatographic data, and that CalDAG-GEFI with G248W mutation 
was stable but unable to exchange nucleotide on Rap1B (unpublished). Furthermore, a homology 
models indicate that serine 341 is a residue buried in the core of the Cdc25 domain that stabilizes 
an elaborate hydrogen bond network. The phenylalanine mutation at this position most likely 
alters CalDAG-GEFIs secondary structure causing the instability. In contrast, glycine 248 is not 
in the core of the protein but in a small loop region between two helices at the base of the Rap1B 
binding pocket. When the tryptophan mutation is modeled, it protrudes up into that binding 
pocket most likely, displacing Rap1B even with CalDAG-GEFI bound by calcium.  
It is clear from the previous example that the structural data we determined in this study 
and our robust functional assay has opened the door to many future studies that will answer 
outstanding questions about the mechanisms regulating CalDAG-GEFI function. Subramanian et 
al., provided biochemical evidence that CalDAG-GEFI is phosphorylated by PKA at serine 587, 
and minimally at serine 116 and 117 leads to impaired Rap1 activation. (100). However, it is 
unclear how these phosphorylation events affect the function of CalDAG-GEFI. Using our 
models and functional assay, we can introduce mutations that mimic phosphorylation (ser116, 
117, 587Asp) and measure their direct effects on nucleotide exchange activity. If there is an 
effect, we could then compare the rate of deuterium exchange between WT and phosphorylated
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CalDAG-GEFI, and we could determine if phosphorylation and calcium regulate CalDAG-GEFI 
antagonistically.  
Our efforts to determine the crystal structure reached an impasse after 3.5 years. During 
that time, we systematically screened over 10,000 crystal growing conditions using various full 
length and truncated forms of CalDAG-GEFI alone and in complex with Rap1B but got no 
crystals. Despite this major setback in our ability to address our specific aim, it gave us a wealth 
of information about the chemical behavior of CalDAG-GEFI which provided data to support 
that hydrogen/deuterium exchange-mass spectrometry would be a viable tool for determining the 
structural consequence of calcium binding. Utilizing the crystal structure of CalDAG-GEFII we 
built a model of autoinhibited CalDAG-GEFI. Using this model, we determined regions that 
must undergo rearrangement in order for CalDAG-GEFI to engage Rap1B. Thus, we measured 
the structural dynamics of calcium binding CalDAG-GEFI using HDX-MS. HDX-MS 
determined the regions in CalDAG-GEFI that become inaccessible or exposed to the solvent 
when calcium binds to its EF hands. While processing our HDX-MS data, a crystal structure of 
CalDAG-GEFI in complex with Rap1B was published (113) (PDB: 6AXF). However, this work, 
could not address any of the same mechanisms we addressed in our work. Instead they used the 
crystal structure to highlight histidine 212 that serves as a pH sensing mechanism activating 
CalDAG-GEFI when the histidine was protonated; a mechanism that regulates CalDAG-GEFI 
activity when the pH inside the cell is low (113). 
In many ways the HDX-MS data provided more information than we would have gained 
from a crystal structure. In particular, the conformational space sampled by CalDAG-GEFI in the 
active or inactive state and defined regions of the protein that were very dynamic, information 
that would have been lost in crystallographic data. Of particular interest, a small region in the 
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REM domain that showed a dramatic increase in deuterium exchange when CalDAG-GEFI is in 
the active state. This is interesting because there is no function associated with the REM domain. 
Other REM domains in Cdc25 domain GEFs have a function associated with allosteric activation 
of Ras, as well as membrane recruitment. (78, 81). Future studies could determine how the 
residues in the REM domain that show calcium-dependent alterations in deuterium uptake affect 
protein stability, catalytic function, or the ability for CalDAG-GEFI to respond to calcium.  
One such study would define regulatory mechanism related to the REM domain much 
like we determined the function of the EF hands. Another interesting project would be to 
determine the role membranes have on the regulation of CalDAG-GEFI. Rap1B is geranyl-
geranylated and sequestered to the membrane. Thus, CalDAG-GEFI has to be recruited to the 
membrane which my alter its catalytic activity. Of note, some preliminary data from the work of 
us and others suggest that the C1 domain of CalDAG-GEFI has lipid-binding properties and this 
s important for membrane association. In our nucleotide exchange assay, the C1 domain had no 
impact on exchange activity, but this of course could be different in the context of the membrane. 
Another important question is how exactly the EF hands contribute to CalDAG-GEFI activity. 
My data shows that EF1 is tightly coupled to CalDAG-GEFI but we still do not understand how 
the inter-domain interactions between EF1 and EF2 are doing to promote the conformational 
rearrangements in CalDAG-GEFI. To determine the interdomain interaction we would perform 
extensive mutagenesis analysis. By making combinatorial mutational analysis we would 
determine the residues within the interface of EF1 and EF2 that provide the coupling energy 
required to displace the linker by EF hand movement. Perhaps it is the unique coupling between 
EF hands that has evolved with platelets giving them one of the most specialized functions of 
any cell in our body.
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